Now Available Online: Archived recording of virtual review webinar #2 led by Dr. Philip Baer

We invite you to view the archived recording of the virtual review webinar which was held on June 20th, led by Dr. Philip Baer featuring the article “Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab” (Tweehuysen et al, Arthritis Rheumatol, Jan 2018) [link to full-text article]

Click to view video: